DOCSLIB.ORG

Why Is There Only One Teva?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Why Is There Only One Teva? A MONTHLY REPORT COVERING NEWS AND INVESTMENT OPPORTUNITIES JOSEPH MORGENSTERN, PUBLISHER November 2004 Vol. XX Issue No.11 You are invited to visit us at our website: http://ishitech.co.il Why is there only One Teva? Why is there only one Teva with annual sales of more As a result of a management decision Teva obtained the than $4.0b? Why has Serono closed down InterPharm? rights to produce Copaxone from the Weizmann Institute. What role do Government support programs play in In due course copaxone became a blockbuster drug nurturing a multinational? whose annual sales are reaching $1.0b. Copaxone lengthens the period between multiple sclerosis attacks. Teva Pharmaceuticals was the result of the merger of three companies: Assia, Zori and Teva. The Not known widely is that 2/3 of Ares Serono’s, the Swiss development of this group reflected the rise of the Italian pharmaceutical giant annual sales are derived pharmaceutical industry in Israel. The first milestone was from Israeli laboratories. The company’s leading product a warehouse for drugs established in Jerusalem in 1901 is bulk recombinant human by Haim Solomon and Moshe Guttel Levin. interferon-beta-1a for the treatment of The initiative to establish a local pharmaceutical industry arose in the early 1930s. Nazi Germany was boycotted http://ishitech.co.il by the Jews in Palestine. As a result the main source of medical supplies was cut off. However, Jewish chemists Why is there only One Teva? began to arrive in Palestine from Germany and other Russia Places First Defense Order with Israel European countries. One consequence being that Radar Warns of Incoming Qassam Rockets expertise in pharmaceuticals rapidly accumulated. Business Week: Israel is Emerging from Financial Drought The pharmaceutical industry gained momentum when Ness Technologies closed Nasdaq pricing at $12-$14 Israeli First “Down Under” the Second World War broke out. Local manufacturing Israel Pushing for Venture Capital Fund with India was almost the only source for drugs within the countries Bear Stearns to Buy 50% of Migdal Capital in the region. Lip-reading on Mobile Phones Eli Lilly invests in startup Remon Medical Unlike Israeli companies like CheckPoint and Comverse UltraSPECT Enters U.S. Market that were formed to address global and international Churches in Mexico Silence Mobile Phones Siliquent Raises $21 million issues Teva Pharmaceuticals came about as a result of Giza, Accel, Formula Vision invest $19m in Transtech a critical need within the country. Dotomi Completes $10.5m. Financing CyOptics Raises $10 million The company was blessed with visionary management InSightec raising $21 million from Shareholders that foresaw the future emergence of the generic drug NICE Video Solution Secures Statue of Liberty industry. Since generics were exact copies of “name” Gteko raises $10m from Pitango, Intel Capital Stem cells as Heart "pacemakers" drugs their price was considerably lower. Major Israelis' Overseas investment Jumped to $737m. international pharmaceutical companies refused to DOCTORAL candidate Yaakov Benenson named one of the license their products to Teva. Teva got around the world’s top young innovators limitations by synthesizing these drugs in their own Israeli Technology Powers US Army Driving Simulator laboratories. Inadvertently this marked the onset of Israeli Yo-Yo Playing Robot generics. Israeli Scientists Awarded Nobel Chemistry Prize Copyright 2004: Israel High-Tech & Investment Report Subscription, bulk copy and reprint information available on request Editorial Offices: P.O.Box 33633, Tel- Aviv 61336, Israel Tel-: +972-3-5235279 Fax: +972-3-5227799 E-mail: [email protected] November 2004 Multiple Sclerosis (MS). Manufactured by InterPharm approved the transaction. Defense Systems’ Vice- and Serono, the product is marketed under the President of marketing, Idan Shimon confirmed the Rebif® commercial brand name. The second report. product came about from research dating from the 1960s by a young scientist named Aliza Eshkol, who Aeronautics Defense Systems, located near Tel-Aviv worked at the gland research laboratories at Israel’s will supply the company’s Aerostar UAV. The product Tel Hashomer Medical Center. The resulting product has also been sold to Angola, Ivory Coast and other Gonal-F, generates 26% of Serono's annual African countries. Aerostar is used to defend oil revenues. installations and other facilities. By a small stretch of the imagination, Serono’s recent Aeronautics Defense Systems recently achieved a decision to close down InterPharm in Israel and to milestone when it signed a joint-venture agreement transfer it to Italy, is understandable.. By moving for UAVs with the General Dynamics Corp. InterPharm to Serono, in due course, the Israeli origin (NYSE:GD). The agreement has already led to one and the drugs developed there will be erased. contract: the US Navy has bought several of However, that doesin no way detracta from the Aeronautics Defense Systems' products. The remarkable technological capabilities of Israel’s Aerostar is manufactured in the US, which Shimon biotechnology researchers. says enables the IDF to use US military aid to buy the system. Government support programs in today’s world are a must and should not be an issue for foreign In order to expand its share of the UAV market, companies seeking to gain a foothold in Israel. Aeronautics Defense Systems bought most of the The research and development commercialization shares of Italian UAV engine-maker Zanzottera companies, affiliated with this country’s major Technologies earlier this year. Zanzottera is now in universities, have available billions of dollars of know- the process of developing more powerful engines for how. They are unable to find enough licensees in Aeronautics Defense Systems larger UAVs, now Israel and would be more than happy to license their under development. patents to overseas groups. Perhaps in the final analysis as to why there is only Israel High-Tech & Investment Report one Teva, can be gleaned from the company’s Published monthly since January 1985 history. Its products were desperately needed by a Publisher and Editor in Chief Middle Eastern population that could not obtain drugs Joseph Morgenstern, B.A. Chem. from overseas. It is also likely that today’s Israeli entrepreneur does not dream of being an Eli Hurwitz, Technology Review Board but would be more likely to emulate the founders of Prof. S.J. Joel-Cohen, MD, FRCS. FRCOG (1996-2002) Mirabilis or ICQ who built businesses in a few years Prof. Hylton Miller, M.B. Ch.B. and rapidly cashed out in the hundreds of millions of Dr. Clive L. Carpel, M.B. Ch.B. dollars. Copy Chief Debbie Mor Russia Places First Defense Order Web Master Marty vonBokel with Israel Graphics Consultant Hebrew daily “Yediot Ahronot” reports that Russia Daniel Morgenstern has made its first defense purchase from Israel. Subscription Inquiries Tel-. +972-3-5235279 Fax. +972 3-5227799 Aeronautics Defense Systems has signed a contract E-mail: [email protected] with the Russian company Irkut, the manufacturer of Annual subscription $95.- per year, for 11 issues, the advanced fighter-bomber Sukhoi Su-30, for Israeli residents add 18% VAT unmanned aerial vehicles (UAV) valued at several Web Edition and Achives millions of dollars. Russia's Ministry of Civil Defense http://ishitech.co.il 2 November 2004 Radar Warns of Incoming Qassam “Why the renewed interest in Israel? First, for a small Rockets country, Israel has lots of start-ups. And start-ups, unlike Western tech giants, didn’t have the luxury of Residents in Jewish settlements in the Gaza strip will cutting back R&D to get through the downturn. So the soon begin to benefit from a novel technology that Israelis kept innovating, even as the global tech affords residents a 15 to 20 second warning of an industry swooned, and fighting surged between incoming Qassam rocket fired from Gaza. Israelis and Palestinians,” writes Business Week. The system, which is connected to a public address system, was used recently for the first time and ”Now there are lots of small survivors with leading- observers judged it to be successful. edge technology in areas such as Internet security, Known as Maamin, Hebrew for “I believe”, the system wireless broadband, and medical devices. No wonder fixes the position from which a rocket is fired and acquisition activity is up by some 25% over the past issues a warning. Using electro-optic sensors and year. Tech exports surged 20% in the first six months advanced computers, Maamin is capable of of 2004, to more than $6 billion, and the Tel-Tech 15 pinpointing both the location of the launch and the index is up 48% in the past twelve months. point where the missile will land, in a calculation lasting. less than a second. ”Israeli high-tech companies are also returning to Wall The missile division at Rafael Israel Armament Street, after a long hiatus. So far this year, three outfits Development Authority, developed the system and a Lipman Electronics Engineering (Nasdaq: LPMA; prototype was built in six weeks following an TASE: LPMA), which develops electronic payment emergency request. systems; PowerDsine (Nasdaq: PDSN), a maker of Maamin was developed according to specifications of integrated circuits for telecoms; and Syneron Medical the ground forces for locating snipers. Success in the (Nasdaq: ELOS) have joined the 70 plus local high- development stages led to an expansion of the tech outfits traded on Nasdaq,” Business Week points specifications to locating the launch sites of Qassam out. rockets. According to the IDF estimates, the average flight time ”There are at least a half-dozen initial public offerings, of a Qassam is about 30 seconds, which is long and a number of follow-on offerings ready to go to enough to seek cover, according to military sources. market by the end of the year,” Lehman Brothers The IDF expects to expand the capabilities of the managing director and head of Israeli business system to enable an immediate response against Leonard G.
Load more

Recommended publications
  • United States Patent (19) 11 Patent Number: 4,871,835 Aviv Et Al
    United States Patent (19) 11 Patent Number: 4,871,835 Aviv et al. (45) Date of Patent: Oct. 3, 1989 54 ANALOGS OF HGH HAVING Lewis et al., Biochem. Biophys, Res. Comm., 92(2), 1980, ANTAGONISTIC ACTIVITY, AND USES pp. 511-516. THEREOF DeGeeter, CA, vol. 99, 1983, #157232u. Russell et al., JBC, 256, 1981, pp. 296-300. (75) Inventors: Haim Aviv; Marian Gorecki, both of Lewis et al., JBC, 253(8), 1978, pp. 2679-2687. Rehovot; Avigdor Levanon, Netania; Goeddel et al., Nature, 281, 1979, pp. 544-548. Amos Oppenheim, Jerusalem; Tikva Seebury et al., Nature, 276, 1978, pp. 795-798. Vogel, Rehovot; Pinhas E. Zeelon, Ross et al., Hormone Design, 1982, pp. 313-318. Hashiva; Menachen Zeevi, Ramat Arieh Gertler et al., Endocrinology, 116(4): 1636-1644 Gan, all of Israel (1985). Alejandro C. Paladini et al., CRC Critical Reviews in 73) Assignee: Bio-Technology General Corp., New Biochemistry, 15(1): 25-56. York, N.Y. Primary Examiner-J. R. Brown 21 Appl. No.: 691,230 Assistant Examiner-Garnette D. Draper Attorney, Agent, or Firm-John P. White 22 Filed: Jan. 14, 1985 57 ABSTRACT Related U.S. Application Data Analogs of hCGH having the activity of naturally occur ring hCH and a similar amino acid sequence varying 63 Continuation-in-part of Ser. No. 514,188, Jul. 15, 1983. from the sequence of natural hCGh by the addition of one or more amino acids, e.g. methione or methionine-leu 511 Int. Cl." .............................................. CO7K 13/00 cine, to the N-terminus of natural hCGH have been pro 52 U.S.
    [Show full text]
  • Alvin Toffler
    A Bantam Book I published in association with William Morrow & Co., Inc. PRINTING HISTORY William Morrow edition published March 1980 5 printings September 1980 A Literary Guild Selection October 1979 A Selection of Preferred Choice Bookplan October 1979 and the Macmillan Book Club May 1980. Serialized in Industry Week, February 1980; East/West Network, February 1980; Across the Board, March 1980; Independent News Alliance, March 1980; Rotarian, April 1980; Mechanix Illustrated, May 1980; Reader's Digest, May 1980; Video Review, May 1980; Journal of Insurance, July 1980; Reader's Digest (Canada), August 1980; and Modern Office Procedures, September 1980. Bantam edition /April 1981 13 printings through May 1989 THE THIRD WAVE also appears in translation: French (Editions Deneol); German (Bertelsmann); Japanese (NHK Books); Spanish (Plaza y Janes and Editorial Diana); Danish (Chr. Erichsens Forlag); Dutch (Uilgenerij L.J. Veen); Hebrew (Am Oved); Portuguese (Distribuidora Record); Serbo-Croatian (Jugoslavia); Swedish) (Esselte Info AB); Turkish (Altin Kitaplar); Chinese (Dushu-Peking); U.K. (William Collins & Sons); India (Pan Books); Greece (Edition Cactus); Poland (Pantswowy Instytut Wydawniczy); Romania (Editura Politica); Portuguese (Livros do Brazil); Indonesia (P.T. Pantja Simpati); Korea (Korean Economic Daily). All rights reserved. Copyright © 1980 by Alvin Toffler. Cover art copyright © 1981 by Bantam Books. No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the publisher. For information address: Bantam Books. ISBN 0-553-24698-4 Published simultaneously in the United States and Canada Bantam Books are published by Bantam Books, a division of Bantam Doubleday Dell Publishing Group, Inc.
    [Show full text]
  • Israeli Biotechnology Strategy Project Realizing Our Potential
    Israeli Biotechnology Strategy Project *** Realizing Our Potential Final Report Tel Aviv, March 2001 Submitted to The Chief Scientist, Ministry of Industry and Trade The Ministry of Finance The IBO by Amsterdam Athens Cambridge Frankfurt Hong Kong Istanbul Johannesburg London Los Angeles Madrid Manila Milan Moscow Munich New Delhi New York Paris S?o Paulo Seoul Singapore Stockholm Tel Aviv Tokyo Toronto Zurich Content A. INTRODUCTION..................................................................................................3 B. EXECUTIVE SUMMARY ....................................................................................4 C. GLOBAL TRENDS AND POTENTIAL FOR ISRAEL ..................................13 D. KEY ISSUES IDENTIFIED IN ISRAEL AND BENCHMARK OF FOREIGN CLUSTERS .......................................................................................23 E. AREAS OF RECOMMENDATIONS ................................................................40 F. CONCLUSION- LONG TERM OBJECTIVES FOR ISRAEL.......................58 G. GLOSSARY OF TERMS....................................................................................59 H. LIST OF INTERVIEWEES................................................................................60 I. BIBLIOGRAPHY..................................................................................................63 APPENDIX .................................................................................................................66 Page 2 /80– March 2001 © 2001 Monitor Company, Inc Introduction
    [Show full text]
  • Galactosidase Gene Arie Rosner, Marian Gorecki *, and Haim Aviv Departments of Virology and Organic Chemistry*, Weizmann Institute of Science, Rehovot, Israel, 76100
    Screening for Highly Active Plasmid Promoters via Fusion to /?-Galactosidase Gene Arie Rosner, Marian Gorecki *, and Haim Aviv Departments of Virology and Organic Chemistry*, Weizmann Institute of Science, Rehovot, Israel, 76100 Z. Naturforsch. 37 c, 441 —444 (1982); received January 13, 1982 Plasmid Promoter, /?-Galactosidase Gene, Escherichia coli A plasmid containing promoter-deleted inactive /?-galactosidase gene [1] was used to select promoters of the pEP121 plasmid [2]. Colonies of cells harboring reactivated /?-galactosidase gene were identified by their red color on McConkey plates. The quantitative amounts of /?-galactosidase produced in each clone were estimated by assaying enzyme activity and by measuring the specific /?-galactosidase protein following fractionation of total cells’ proteins on polyacrylamide gel. A wide range of enzyme activities was observed. The most active promoter isolated was shown to promote /?-galactosidase production more efficiently, compared with the original /?-galactosidase promoter, amounting to 20% of all cell proteins. Such highly active promoters may be utilized in the future, to promote expression of cloned genes in bacteria. Introduction gene and E. coli strain MC 1061, restriction minus, deleted in the lactoase operon [1] were received It was previously shown that bacterial promoters from Dr. M. J. Casadaban and given to us by Dr. M. can promote expression of foreign genes in bacteria Mevorach. [3, 4]. The amount of protein produced depends Preparation of plasmid: Extraction of plasmid mainly on the activity of the promoter itself. The DNA was performed according to Betlach et al. [5]. isolation and molecular manipulation of bacterial Transformation of cells with plasmid DNA was promoters became, therefore, of prime interest in carried out as described by Cohen et al.
    [Show full text]
  • Accelerating Medical Solutions in Israel: Building a Global Life Science Industry
    Volume 6 May 2008 May Financial Innovations Lab Report Lab Innovations Financial Accelerating Medical Solutions in Israel: Building a Global Life Science Industry FINANCIAL INNOVATIONS LAB REPORT Volume 6 May 2008 May Financial Innovations Lab Report Lab Innovations Financial Accelerating Medical Solutions in Israel: Building a Global Life Science Industry FINANCIAL INNOVATIONS LAB REPORT Acknowledgments This "Financial Innovations Lab Report for Accelerating The Israel Presidential Conference "Facing Tomorrow" will Medical Solutions in Israel: Building a Global Life Science be dedicating a special session to the translation of medical Industry" was prepared by Glenn Yago, Ronit Purian-Lukatch innovation in Israel into business success, based on the and Ilan Vaknin. Liza Ireni-Saban drafted Appendix 1 on current report. We thank President Shimon Peres for his regulation and legislation concerning clinical and genetic vision and inspiration of the process whereby the Financial trials. We are grateful to all participants of the Financial Innovations Lab took place. Innovations Lab and workgroups for their contributions to the ideas summarized in this report. A list of participants may be found in Appendix 2. We give special thanks to the Sacta-Rashi Fund and the Yeshaya Horowitz Foundation for their interest and continuing support of this work. The Milken Institute is an independent economic think tank whose mission is to improve the lives and economic conditions of diverse populations in the US and around the world by helping business
    [Show full text]
  • Galactosidase Gene Arie Rosner, Marian Gorecki *, and Haim Aviv Departments of Virology and Organic Chemistry*, Weizmann Institute of Science, Rehovot, Israel, 76100
    Screening for Highly Active Plasmid Promoters via Fusion to /?-Galactosidase Gene Arie Rosner, Marian Gorecki *, and Haim Aviv Departments of Virology and Organic Chemistry*, Weizmann Institute of Science, Rehovot, Israel, 76100 Z. Naturforsch. 37 c, 441 —444 (1982); received January 13, 1982 Plasmid Promoter, /?-Galactosidase Gene, Escherichia coli A plasmid containing promoter-deleted inactive /?-galactosidase gene [1] was used to select promoters of the pEP121 plasmid [2]. Colonies of cells harboring reactivated /?-galactosidase gene were identified by their red color on McConkey plates. The quantitative amounts of /?-galactosidase produced in each clone were estimated by assaying enzyme activity and by measuring the specific /?-galactosidase protein following fractionation of total cells’ proteins on polyacrylamide gel. A wide range of enzyme activities was observed. The most active promoter isolated was shown to promote /?-galactosidase production more efficiently, compared with the original /?-galactosidase promoter, amounting to 20% of all cell proteins. Such highly active promoters may be utilized in the future, to promote expression of cloned genes in bacteria. Introduction gene and E. coli strain MC 1061, restriction minus, deleted in the lactoase operon [1] were received It was previously shown that bacterial promoters from Dr. M. J. Casadaban and given to us by Dr. M. can promote expression of foreign genes in bacteria Mevorach. [3, 4]. The amount of protein produced depends Preparation of plasmid: Extraction of plasmid mainly on the activity of the promoter itself. The DNA was performed according to Betlach et al. [5]. isolation and molecular manipulation of bacterial Transformation of cells with plasmid DNA was promoters became, therefore, of prime interest in carried out as described by Cohen et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,229,003 B1 Aviv Et Al
    USOO6229003B1 (12) United States Patent (10) Patent No.: US 6,229,003 B1 Aviv et al. (45) Date of Patent: May 8, 2001 (54) PRODUCTION OF BOVINE GROWTH OTHER PUBLICATIONS HORMONE BY MICROORGANISMS Seeburg et al., Nature 276:795–798 (1978). (75) Inventors: Haim Aviv, Rehovot; Eliyahu Keshet, Lingappa et al., Cell Biol. 74:2432-2436 (1977). Ramat; Marian Gorecki, Rehovot, Cohen et al., P.N.A.S. 70 (11):3240–3244 (1973); and. Chang et al., P.N.A.S. 71 (4): 1030-1034 (1974). Arie Rosner, Nes Ziona, all of (IL) Nilson et al. (1979), “Purificatio of Pre-prolactin mRNA (73) Assignee: Yeda Research and Development from Bovine Anterior Pituitary Glands”, J. Biol. Chem. Company Ltd., Rehovot (IL) 254:1516-1520. Keiichi Itakura and Arthur D. Riggs (1980), “Chemical (*) Notice: Subject to any disclaimer, the term of this DNA Synthesis and Recombinant DNA Studies”, Science patent is extended or adjusted under 35 209:1401-1405. U.S.C. 154(b) by 0 days. Hunt and Dayhoff (1976), Atlas of Protein Sequence and Structure, (National Biomed. Res. Fund.) Washington, D.C., Vol. 5, Supp. 2, p. 11. (21) Appl. No.: 08/457,405 Edge et al. (1981), “Total Synthesis Of A Human Leukocyte (22) Filed: Jun. 1, 1995 Interferon Gene”, Nature 292:756–762. Coutelle et al. (1978), “Use of Matrix-Immobilised Recom Related U.S. Application Data binant Plasmids To Purify Chain-Specific Rabbit Globin Complementary DNAs, Gene 3:113-122. (63) Continuation of application No. 08/317.248, filed on Oct. 3, 1994, now abandoned, which is a continuation of application Sassavage et al., Federation Proceedings, Abstracts, (1979), No.
    [Show full text]
  • Purification of Biologically Active Globin Messenger RNA By
    Proc. Nat. Acad. Sci. USA Vol. 69, No. 6, pp. 1408-1412, June 1972 Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic acid-Cellulose (p.ly (A)-richi inRNA/rabbit globin niRN A/ascites tumiior cell-free systelml) HAIM AVIV ANI) PHILIP LEI)ER Laboratory of Molecular Genetics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20014 Coinnmunicatel by E. IR. Stadtrnan, March 22, 1972 ABSTRACT A convenient technique for the partial MATERIALS AND METHODS purification of large quantities of functional, poly(adenylic acid)-rich mRNA is described. The method depends upon The sources of many of the reagents used in this study have annealing poly(adenylic acid)-rich mRNA to oligothymi- been indicated (10). For the synthesis of oligo(dT)-cellulose, dylic acid-cellulose columns and its elution with buffers Whatman cellulose powder CC 41 was obtained from Reeve of low ionic strength. Biologically active rabbit globin Angel; thymidine-5'-monophosphate, from Schwarz-Mann; mRNA has been purified by this procedure and assayed for its ability to direct the synthesis of rabbit globin in a and NN'-dicyclohexylearbodiimide, from Aldrich. [3H]- cell-free extract of ascites tumnor. Inasmuch as various Leucine (specific activity, 26 Ci/mmol); ['4C]leucine (specific mammalian mRNAs appear to be rich in poly(adenylic activity, 263 Ci/mol) and [14C]valine (specific activity, 219 acid) and can likely be translated in the ascites cell-free Ci/mol), from New England Nuclear; [14C]lysine (specific extract, this approach should prove generally useful as an i -itial step in the isolation of specific mRNAs.
    [Show full text]
  • President's Report 2018
    VISION COUNTING UP TO 50 President's Report 2018 Chairman’s Message 4 President’s Message 5 Senior Administration 6 BGU by the Numbers 8 Building BGU 14 Innovation for the Startup Nation 16 New & Noteworthy 20 From BGU to the World 40 President's Report Alumni Community 42 2018 Campus Life 46 Community Outreach 52 Recognizing Our Friends 57 Honorary Degrees 88 Board of Governors 93 Associates Organizations 96 BGU Nation Celebrate BGU’s role in the Israeli miracle Nurturing the Negev 12 Forging the Hi-Tech Nation 18 A Passion for Research 24 Harnessing the Desert 30 Defending the Nation 36 The Beer-Sheva Spirit 44 Cultivating Israeli Society 50 Produced by the Department of Publications and Media Relations Osnat Eitan, Director In coordination with the Department of Donor and Associates Affairs Jill Ben-Dor, Director Editor Elana Chipman Editorial Staff Ehud Zion Waldoks, Jacqueline Watson-Alloun, Angie Zamir Production Noa Fisherman Photos Dani Machlis Concept and Design www.Image2u.co.il 4 President's Report 2018 Ben-Gurion University of the Negev - BGU Nation 5 From the From the Chairman President Israel’s first Prime Minister, David Ben–Gurion, said:“Only Apartments Program, it is worth noting that there are 73 This year we are celebrating Israel’s 70th anniversary and Program has been studied and reproduced around through a united effort by the State … by a people ready “Open Apartments” in Beer-Sheva’s neighborhoods, where acknowledging our contributions to the State of Israel, the the world and our students are an inspiration to their for a great voluntary effort, by a youth bold in spirit and students live and actively engage with the local community Negev, and the world, even as we count up to our own neighbors, encouraging them and helping them strive for a inspired by creative heroism, by scientists liberated from the through various cultural and educational activities.
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,716,637 Anselem Et Al
    US005716637A United States Patent 19 11 Patent Number: 5,716,637 Anselem et al. 45 Date of Patent: *Feb. 10, 1998 54 SOLID FAT NANOEMULSIONS AS WACCNE 56) References Cited DELVERY WEHICLES U.S. PATENT DOCUMENTS Inventors: Shimon Anselem, Rehovot, Israel; 4,880,635 11/1989 Janoff...................................... 424/450 George H. Lowell, Baltimore, Md.; 5,023,271 6/1991 Vigne ... 514/.458 Haim Aviv, Rehovot; Doron 5,171,737 12/1992 Weiner ........................................ 514/3 Friedman, Carmei Yosef, both of Israel 5,188,837 2/1993 Domb ..... 424/450 5,284.663 2/1994 Speaker ...... 424/489 73) Assignees: Pharmos Corporation, New York, 5,302.401 4/1994 Livesidge ... 424/489 N.Y.; The United States of America as 5,306,508 4/1994 Kossovsky . 424/493 represented by the Secretary of the 5,308,624 5/1994 Maircent ... 424/427 Army, Washington, D.C. 5,576,016 11/1996 Amselem ................................ 424/450 FOREIGN PATENT DOCUMENTS * Notice: The term of this patent shall not extend 0315079 5/1989 European Pat. Off.. beyond the expiration date of Pat. No. 0506 197 9/1992 European Pat. Off.. 5,576,016. WO91/07171 5/1991 WIPO. 21 Appl. No.: 553,350 OTHER PUBLICATIONS CRC Press, Inc., Liposome Technology, 2nd Edition, vol. 1, 22 PCT Filled: May 18, 1994 Chapter 28, p. 501, Liposome Preparation and Related Techniques, edited by Gregory Gregoiadis, Ph.D., "A 86 PCT No.: PCT/US94/05589 Large-Scale Method For the Preparation. Of Sterile And Nonpyrogenic Liposomal Formulations Of Defined Size S371 Date: Nov. 16, 1995 Distributions For Clinical Use'.
    [Show full text]
  • High-Level Expression of Enzymatically Active Human Cu/Zn Superoxide Dismutase in Escherichia Coli (Bacterial Expression Vector/A PL/Ribosome Binding Site) JACOB R
    Proc. Natl. Acad. Sci. USA Vol. 83, pp. 7142-7146, October 1986 Biochemistry High-level expression of enzymatically active human Cu/Zn superoxide dismutase in Escherichia coli (bacterial expression vector/A PL/ribosome binding site) JACOB R. HARTMAN, TANIA GELLER, ZIVA YAVIN, DANIEL BARTFELD, Dov KANNER, HAIM Aviv, AND MARIAN GORECKI Bio-Technology General (Israel) Ltd., Kiryat Weizmann, Rehovot 76326 Israel Communicated by Richard Axel, May 13, 1986 ABSTRACT Expression of human Cu/Zn superoxide dis- interest has evolved in the therapeutic potential of SOD. A mutase (SOD) with activity comparable to the human eryth- wide range of clinical applications has been suggested. These rocyte enzyme was achieved in Escherichwa coli by using a include prevention of oncogenesis and tumor promotion, vector containing a thermoinducible X PL promoter and a reduction of the cytotoxic and cardiotoxic effects of ,8-lactamase-derived ribosomosal binding site. The recombi- anticancer drugs (5), anti-inflammatory action (6), and pro- nant human SOD was found in the cytosol ofdisrupted bacteria tection against reperfusion damage of ischemic tissues (7). In and represented >10% of the total bacterial protein. The addition, there is much interest in studying the effects ofSOD enzyme was purified to homogeneity by salt precipitation, gel on the aging process (8). filtration chromatography, and ion exchange chromatography. The exploration ofthe therapeutic potential ofhuman SOD The active enzyme was obtained in high yield only when 1 mol has been hindered by its limited availability. The enzyme is of copper and 1 mol of zinc were incorporated into each mol of a dimeric metalloprotein composed of identical noncovalent- subunit during bacterial growth or by reconstitution of the ly linked subunits, each of 16 kDa and containing one atom apoenzyme.
    [Show full text]
  • May 23, 1972, NIH Record, Vol. XXIV, No. 11
    the U. S. DEPARTMENT OF >May 23 , 197Record2 NATIONAL INSTITUTES OF HEALTH HEALTH, EDUCATION, AND WELFARE Vol. XXIV, No. 11 Research Teams Establish New Approach NIEHS Role Is Evaluated Medical Award Presented To the Study of Genetic Blood Diseases At Congressional Hearing To Dr. Makio Murayama Three teams of scientists participating in the Special Virus Cancer Program of the National Cancer Institute, have successfully reversed For Sickle Cell Studies the normal flow of genetic activity among fundamental cell chemicals to The Rev. Dr. Martin Luther permit reconstruction of a portion King, Jr. Medical Achievement of the gene for red blood cell Award will be presented to Dr. Two Framingham Study protein. Makio Murayama, the National In- Their findings establish a new stitute of Arthritis and Metabolic Directors Receive First approach to the study of genetic Diseases' noted sickle cell anemia diseases of the blood such as researcher. Eleanor Dana Award thalassemia. The award, which highlights Dr. One team, made up of NIH sci- Murayama's research in elucidat- Drs. William B. Kannel and entists reported their results in a ing the molecular concept of sick- Thomas R. Dawber, Director and recent issue of the Proceedings of ling, will be given to the researcher former Director, respectively, of the National Academy of Sciences. at a May 31st banquet. Noted NHLI's Framingham Heart Disease The researchers are Drs. Jeffrey guests who are expected at the Epidemiology Study, are co-recipi- Ross and Edward Scolnick of NCI's banquet include Aretha Franklin, ents of the American Health Foun- Viral Leukemia and Lymphoma Bill Cosby, Ossie Davis, and Count Branch, and Drs.
    [Show full text]